๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

RecruitingNAAges 18 Years - 85 YearsAllInstituto Nacional de Cancerologia de Mexico
NCT06238882 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this interventional phase III clinical trial is to evaluate objective intracranial response rate (iORR) after a treatment with total cranial radiation therapy plus concomitant transdermal nitroglycerin (NTG) addition or total cranial radiation therapy only in patients with stage IV non-small cell lung cancer with brain metastases and EGFR mutation. The main questions it aims to answer are: Determine progression-free survival (PFS) to CNS and overall survival (OS). Evaluate and compare the quality of life (QoL) of patients during and after treatment. Evaluate the cognitive function of patients before, during and after treatment. Evaluate treatment-associated toxicity to grade adverse treatment events Evaluation of HIF1ฮฑ, VEGF and ROS1 in peripheral blood before and after nitroglycerin treatment. All participants will have laboratory tests at the beginning and end of radiati

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients diagnosed with advanced non-small cell lung cancer (which includes de novo stage IIIB-IV, according to the 8th edition AJCC, or recurrent disease), documented by histology and/or cytology. * Presence of brain metastases, candidates for treatment with holocranial radiation therapy. * Documented EGFR sensitivity mutation. * Disease measurable by criteria: The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM). * 18 years and up. * Functional status, by ECOG scale 0-2 * Life expectancy at least 12 weeks. * Not receive vasodilator treatment as calcium channel blockers. * Electrocardiogram * Neutrophil count 1.5 x 103/mm3, platelet count \>100 x (103/mm3). * Serum bilirubin should be 1.5 of the upper normal limit (ULN, upper normal limit). * AST and/or ALT 2 ULN (or 5 x ULN in patients with liver metastases). * Serum creatinine 1.5 (ULN), or creatinine clearance 60ml/min. * Ability to comply with study and follow-up procedures. * Informed written (signed) consent to participate in the study. * Have tumor tissue (paraffin blocks from diagnostic biopsy) obtained before systemic treatment Exclusion Criteria: * Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, ischemic heart disease, liver, kidney disease). * Patients with a history of allergy to glyceryl tinistate * Any other malignant pathology within the previous 5 years (except for cervical carcinoma in situ or basal-cell skin cancer, treated appropriately). * Pregnant and/or breastfeeding women. * Meningeal carcinomatosis corroborated by cytopathological study. Disposal Criteria: * Failure to follow protocol rules. * Loss of patient follow-up. * Patients who express their desire not to continue the study. * Patients with unacceptable toxicity
๐Ÿ’Š

What it tests

  • Nitroglycerin
๐Ÿ“

Where

1 site
Instituto Nacional de Cancerologia
Mexico City, Mexico
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy